centchroman has been researched along with medroxyprogesterone acetate in 1 studies
| Studies (centchroman) | Trials (centchroman) | Recent Studies (post-2010) (centchroman) | Studies (medroxyprogesterone acetate) | Trials (medroxyprogesterone acetate) | Recent Studies (post-2010) (medroxyprogesterone acetate) |
|---|---|---|---|---|---|
| 157 | 12 | 47 | 5,123 | 1,115 | 1,099 |
| Protein | Taxonomy | centchroman (IC50) | medroxyprogesterone acetate (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 0.924 | |
| Glucocorticoid receptor | Homo sapiens (human) | 0.013 | |
| Progesterone receptor | Homo sapiens (human) | 2.5081 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.019 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 1.197 | |
| Androgen receptor | Homo sapiens (human) | 0.0061 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.279 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.019 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.019 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.019 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.197 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 1.4059 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 4.0405 | |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | 1.8 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.924 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, T; Almuqbil, M; Alshehri, AM; Alshehri, S; Amin, F; Ara, R; Bader, GN; Hamid, L; Malik, A; Mir, SA; Shakeel, F; Wani, SUD | 1 |
1 trial(s) available for centchroman and medroxyprogesterone acetate
| Article | Year |
|---|---|
Evaluation of the Safety and Efficacy of Ormeloxifene, a Selective Estrogen Receptor Modulator and Medroxyprogesterone Acetate in Women with Non-Structural Abnormal Uterine Bleeding: A Randomized Clinical Trial.
Topics: Female; Humans; Medroxyprogesterone Acetate; Prospective Studies; Quality of Life; Selective Estrogen Receptor Modulators; Uterine Hemorrhage | 2022 |